Pfizer Inc.

PFE Stock Report Card

Today's performance

58%

Performance

Score:

10/100

PFE returned -28.84% in the last 12 months. Based on SPY's performance of -8.73%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

Score:

63/100

22 analysts offer 12-month price targets for PFE. Together, they have an average target of 60.44, the most optimistic target put PFE at 141.39 within 12-months and the most pessimistic has PFE at 44. These analyst ratings are from our partners at Financial Modeling Prep (https://site.financialmodelingprep.com/) and Alpha Vantage (https://www.alphavantage.co/).

Sentiment

Score:

70/100

PFE had a bullish sentiment score of 70.28% across Twitter and StockTwits over the last 12 months. It had an average of 426.45 posts, 10,553.41 comments, and 36,617.07 likes per day.

Technicals

Score:

36/100

PFE receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Earnings

Score:

71/100

PFE has missed earnings 2 times in the last 20 quarters.

Profit

Score:

51/100

Out of the last 20 quarters, PFE has had 18 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

Score:

45/100

PFE has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Dividend

Score:

100/100

PFE's most recent dividend was $0.32 per share, based on a share price of $36.32. It was a payout ratio of 51.37% compared to their total earnings.

Pfizer Inc. Summary

New York Stock Exchange / PFE

Healthcare

Drug Manufacturers—General

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pluto is a technology provider that provides you with information, software, and automation tools for the purpose of investment education, but it does not make investment recommendations of securities, investment strategies, or account types, either in general or individualized for you or any other subscriber. If you want to receive individualized investment advice, you should consult with your own financial adviser. Pluto also does not provide you with legal, tax, or accounting advice. You agree that you understand that Pluto is not an investment adviser or a broker-dealer and does not have a fiduciary duty to you or a duty to act in your best interests. Pluto can help you back-test the historical performance of strategies that you create, but it does not recommend strategies and reminds you that the historical performance of a strategy is not a reliable predictor of future results for that strategy. Pluto uses third-party information, for example, about securities market data, that it reasonably believes to be reliable, but it does not warrant that the information is complete, accurate, or up-to-date, and as discussed further below, Pluto does not provide any warranty of merchantability or warranty for a particular purpose for that third-party market data or other information. Investing involves risk, including the risk of loss, and you should not use the Pluto technology in connection with investments unless you are able to and intend to evaluate the technology and the risks and make your own self-directed investment decisions.

Power up your portfolio

Build a portfolio of your favorite stocks

Pluto makes it easy to build investing strategies and automate your portfolio

See how

Checkout Similar Companies

PFE scored highly on our reportcard. Here are some similar companies and how they performed.

Eli Lilly & Co.

$LLY Stock Report Card

UNITEDHEALTH GROUP INCORPORATED (Delaware)

$UNH Stock Report Card

Johnson & Johnson

$JNJ Stock Report Card

Novo-Nordisk A/S

$NVO Stock Report Card

Merck & Co., Inc.

$MRK Stock Report Card

ABBVIE INC.

$ABBV Stock Report Card

AstraZeneca PLC

$AZN Stock Report Card

Novartis AG

$NVS Stock Report Card

View all stock report cards

Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.